Transcriptome changes induced by docetaxel in human mammary cell lines expressing different levels of ERBB2

International Journal of Molecular Medicine

Volumn 23, Issue 6, 2009, Pages 733-743

  Dos Santos, M L ^a   Gimenes, K P ^a   Silva Jr , W A ^a   Nagai, Maria Aparecida ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Drug resistance; ERBB2; SAGE

Indexed keywords

ALPHA ACTININ 1; APOLIPOPROTEIN A1; ASPARTYL AMINOPEPTIDASE; CAVEOLIN 1; DOCETAXEL; ELECTRON TRANSFERRING FLAVOPROTEIN; ELECTRON TRANSFERRING FLAVOPROTEIN BETA POLYPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HELIX LOOP HELIX PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE H1; INHIBITOR OF DIFFERENTIATION 1; ISOLEUCINE TRANSFER RNA LIGASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NUCLEOPORIN; NUCLEOPORIN 62; PHOSPHATIDYLSERINE SYNTHASE; PROTOPORPHYRINOGEN OXIDASE; SECRETED FRIZZLED RELATED PROTEIN 1; SLIT2 PROTEIN; SOMATOMEDIN BINDING PROTEIN 4; SYNTAXIN; SYNTAXIN 3; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR SNF; TRANSCRIPTION FACTOR YY1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERIAL ANALYSIS OF GENE EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; TAXOIDS; TRANSCRIPTION, GENETIC;

EID: 67649552824     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000187     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2008.
2. Lønning PE: Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 4: 177-185, 2003.
3. Pasquier E and Kavallaris M: Microtubules: a dynamic target in cancer therapy. IUBMB Life 60: 165-170, 2008.
4. Noguchi S: Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 97: 813-820, 2006.
5. Gelmon K: The taxoids: paclitaxel and docetaxel. Lancet 344: 1267-1272, 1994.
6. Herbst RS and Khuri FR: Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 29: 407-415, 2003.
7. Hamilton A and Hortobagyi G: Chemotherapy: what progress in the last 5 years? J Clin Oncol 23: 1760-1775, 2005.
8. Fulton B and Spencer CM: Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 51: 1075-1092, 1996.
9. McDonald SL, Stevenson DA, Moir SE, Hutcheon AW, Haites NE, Heys SD and Schofield AC: Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 41: 1086-1094, 2005.
10. Shalli K, Brown I, Heys SD and Schofield AC: Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19: 1299-1301, 2005.
11. Brown I, Shalli K, McDonald SL Moir SE, Hutcheon AW, Heys SD and Schofield AC: Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res 6: R601-R607, 2004.
12. Myioshi Y, Taguchi T, Kim SJ, Tamaki Y and Noguchi S: Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancer. Breast Cancer 12: 11-15, 2005.
13. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y and Noguchi S: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95: 255-259, 2001.
14. Ooe A, Kato K and Nogushi S: Possible involvement of CCT5, RGS3 and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 101: 305-315, 2007.
15. Yu D, Liu B, Jing T, et al: Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16: 2087-2094, 1998.
16. Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR and Tortora G: Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer 85: 710-715, 2000.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
18. Nagai MA, Marques LA, Torloni H and Brentani MM: Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50: 412-417, 1993.
19. Azambuja E, Durbecq V, Rosa DD, Colozza M, Larsimont D, Piccart-Gebhart M and Cardoso F: HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 19: 223-232, 2008.
20. Nabholtz JM and Gligorov J: Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opin Pharmacother 6: 1555-1564, 2005.
21. Harris RA, Eichholtz TJ, Hiles ID, Page MJ and O'Hare MJ: New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer 80: 477-484, 1999.
22. Chomczynsk P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
23. Velculescu VE, Zhang L, Vogelstein B and Kinzler KW: Serial analysis of gene expression. Science 270: 484-487, 1995.
24. dos Santos ML, Palanch CG, Salaorni S, Da Silva WA Jr and Nagai MA: Transcriptome characterization of human mammary cell lines expressing different levels of ERBB2 by serial analysis of gene expression. Int J Oncol 28: 1441-1461, 2006.
25. Hernández-Vargas H, Palacios J and Moreno-Bueno G: Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26: 2902-2913, 2007.
26. Fitzpatrick FA and Wheeler R: The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 3: 1699-1714, 2003.
27. Hernández-Vargas H, Palacios J and Moreno-Bueno G: Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle 6: 780-783, 2007.
28. Chrenek MA, Wong P and Weaver VM: Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res 3: 224-229, 2001.
29. Morin PJ: Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 6: 169-172, 2003.
30. Phan E, Ahluwalia A and Tarnawski AS: Role of SPARC - matricellular protein in pathophysiology and tissue injury healing. Implications for gastritis and gastric ulcers. Med Sci Monit 13: RA25-RA30, 2007.
31. Fukunaga-Kalabis M and Herlyn M: Unraveling mysteries of the multifunctional protein SPARC. J Invest Dermatol 127: 2497-2498, 2007.
32. Podhajcer OL, Benedetti L, Girotti MR, Prada F, Salvatierra E and Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27: 523-537, 2008.
33. Jones C, Mackay A and Grigoriadis A, et al: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64: 3037-3045, 2004.
34. Watkins G, Douglas-Jones A, Bryce R, Mansel RE and Jiang WG: Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72: 267-272, 2005.
35. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ and Jain RK: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 260: 2497-2503, 2000.
36. Sung SY, Hsieh CL, Wu D, Chung LW and Johnstone PA: Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 31: 36-100, 2007.
37. Tai IT, Dai M, Owen DA and Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 115: 1492-1502, 2005.
38. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D and Tai IT: SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer 98: 1810-1819, 2008.
39. Makino Y, Kanemaki M and Koga A, et al: Chromosome mapping and expression of human tip49 family genes. DNA Seq 11: 145-148, 2000.
40. Wood MA, McMahon SB and Cole MD: An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell 5: 321-330, 2000.
41. Bauer A, Huber O and Kemler R: Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein. Proc Natl Acad Sci USA 95: 14787-14792, 1998.
42. Feng Y, Lee N and Fearon ER: TIP49 regulates beta-catenin-mediated neoplastic transformation and T-cell factor target gene induction via effects on chromatin remodeling. Cancer Res 63: 8726-8734, 2003.
43. Gartner W, Rossbacher J, Zierhut B, et al: The ATP-dependent helicase RUVBL1/TIP49a associates with tubulin during mitosis. Cell Motil Cytoskeleton 56: 79-93, 2003.
44. Fielding AB, Dobreva I, McDonald PC, Foster LJ and Dedhar S: Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. J Cell Biol 180: 681-689, 2008.
45. Legate KR, Montañez E, Kudlacek O and Fässler R: ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 7: 20-31, 2006.
46. Mackay A, Jones C, Dexter T, et al: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22: 2680-2688, 2003.
47. Sugata N, Li S, Earnshaw WC, et al: Human CENP-H multimers colocalize with CENP-A and CENP-C at active centromere - kinetochore complexes. Hum Mol Genet 9: 2919-2926, 2000.
48. Hemmerich P, Weidtkamp-Peters S, Hoischen C, Schmiedeberg L, Erliandri I and Diekmann S: Dynamics of inner kinetochore assembly and maintenance in living cells. J Cell Biol 180: 1101-1114, 2008.
49. Cimini D and Degrassi F: Aneuploidy: a matter of bad connections. Trends Cell Biol 15: 442-451, 2005.
50. Amor DJ, Kalitsis P, Sumer H and Choo KH: Building the centromere: from foundation proteins to 3D organization. Trends Cell Biol 14: 359-368, 2004.
51. Fukagawa T, Mikami Y, Nishihashi A, et al: CENP-H, a constitutive centromere component, is required for centromere targeting of CENP-C in vertebrate cells. EMBO J 20: 4603-4617, 2001.
52. Orthaus S, Ohndorf S and Diekmann S: RNAi knockdown of human kinetochore protein CENP-H. Biochem Biophys Res Commun 348: 36-46, 2006.
53. Tomonaga T, Matsushita K, Ishibashi M, et al: Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res 65: 4683-4689, 2005.
54. Liao WT, Song LB, Zhang HZ, et al: Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res 13: 508-514, 2007.
55. Shigeishi H, Higashikawa K, Ono S, et al: Increased expression of CENP-H gene in human oral squamous cell carcinomas harboring high-proliferative activity. Oncol Rep 16: 1071-1075, 2006.